Loading...
Market
Which regulatory body will first approve a product developed using LatProtRL by end of 2025?
2
Resolution / Starting Odds
FDA (USA) • 25%
EMA (EU) • 25%
MHRA (UK) • 25%
Other • 25%
Official announcements from regulatory bodies, press releases, or reputable news sources
Story
AI Breakthrough: LatProtRL and Ex-Meta Scientists Develop Novel Proteins
Jul 18, 2024, 11:51 AM
Scientists have developed a groundbreaking AI method called LatProtRL that promises to revolutionize protein optimization, a crucial process for drug discovery and biotechnology. Former Meta scientists have unveiled an AI model capable of generating novel proteins not found in nature. These advancements in protein design, including sequence generation, could transform biotechnology and drug development. The AI-generated proteins represent a significant leap in bioengineering, paving the way for real-world applications.
View original story
Similar markets
FDA • 25%
EMA • 25%
MHRA • 25%
Other • 25%
FDA (US) • 25%
EMA (European Union) • 25%
MHRA (UK) • 25%
Other • 25%
European Central Bank • 25%
BaFin (Germany) • 25%
US SEC • 25%
Other • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
PMDA (Japan) • 25%
Other • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
MHRA (UK) • 25%
Other • 25%
European Medicines Agency (EMA) • 25%
Health Canada • 25%
Japan's PMDA • 25%
Other • 25%
Only FDA • 25%
FDA and EMA • 25%
FDA, EMA, and MHRA • 25%
None • 25%
European Medicines Agency (EMA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Other • 25%
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
